PWM7: THE EFFECT AND ECONOMIC IMPACT OF STANDARDIZED ORDERS ON THE PREVENTION AND TREATMENT OF PONV IN HOSPITALIZED GYNECOLOGICAL SURGERY PATIENTS  by Marra, C et al.
Abstracts 167
PWM5
HEALTH CARE USE ATTRIBUTABLE TO 
PROSTATE NON-SELECTIVE ALPHA-1 
ANTAGONIST INITIATION FOR BENIGN 
PROSTATIC HYPERPLASIA (BPH)
Chrischilles EA1, Rubenstein LM1, Gilden D2, Shah H3
1University of Iowa, Iowa City, IA, USA; 2Jen Associates, Inc, 
Cambridge, MA, USA; 3Boehringer Ingelheim Pharmaceuticals, 
Inc, Ridgefield, CT, USA
OBJECTIVE: The prescription of prostate non-selective
alpha-1 antagonists (terazosin, doxazosin, prazosin) may
require extra health care visits for dose titration and for
monitoring treatment safety and effectiveness. From a
retrospective cohort study using pension related fee-for-
service supplementary Medigap health claims data, we
estimated the impact of alpha-1 antagonist initiation on
health care use and costs for men with BPH. METHODS:
Claims data from a two year period included medical and
prescription drug information for 53,824 men with BPH.
We compared men who initiated alpha-1 antagonists
with a random sample of nonusers. Inpatient and outpa-
tient costs were calculated as the sum of the Medicare
paid amount, the Medigap co-pay amount, and the Medi-
gap deductible amount. Comparisons used generalized esti-
mating equation (GEE) or Poisson regression methods to
estimate the change from four months pre- to four months
post-initiation and an imputed date for non-users. This pe-
riod coincided with the recommended time for treatment ti-
tration and a period of increased hypotensive event risk in
this population. RESULTS: Adjusting for baseline health
care use, age, and co-morbidity, alpha-1 antagonist initia-
tors had a mean of 4.2 more physician visits post-initiation
than men who did not initiate among those who did not
use other antihypertensives and 5.8 more visits among men
who did use antihypertensives (p  0.05). The correspond-
ing adjusted difference in cost of physician visits was $176
per man for those who did not use other antihypertensives
and $267 for those who did use other antihypertensives (p
 0.05). Initiation was also significantly associated with an
increase of 0.15 hospital stays per 1,000 person-days
among non-users of other antihypertensives and an in-
crease of 0.24 hospital stays per 1,000 person-days among
users of other antihypertensives. CONCLUSION: The in-
creased number of physician visits, hospital stays, and phy-
sician visit costs post-initiation should be considered in
cost-effectiveness analyses of BPH treatments.
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COST-EFFECTIVENESS OF INTRAVAGINAL 
PROSTAGLANDIN E2 GEL AND INTRAVAGINAL 
MISOPROSTOL FOR PREINDUCTION
CERVICAL RIPENING
Gagne AL, Daneshfar S
Northeastern University, Boston, MA, USA
OBJECTIVES: To compare the cost-effectiveness of in-
travaginal prostaglandin E2 gel and intravaginal miso-
prostol tablets for preinduction cervical ripening. METH-
ODS: This study was a modeled cost-effectiveness analysis
from the hospital perspective. A decision analysis was
used to estimated costs and percentage of women achiev-
ing vaginal delivery with either intravaginal prostaglan-
din E2 or intravaginal misoprostol. Costs were assessed
in 1999 dollars and obtained from Brigham and Women’s
Hospital in Boston, Massachusetts. Probabilities and per-
centage of patients achieving vaginal delivery within 24
hours were obtained by meta-analysis of published trails.
Health resoursed used for the rate of delivery after each
dose of the study agents were obtained through an expert
physician pane. RESULTS: The primary outcome mea-
sures were direct medical costs, in 1999 dollars, and ef-
fect was measured as percentage of patients achieving
successful cervical ripening, leading to labor induction
and vaginal delivery before use of an alternative method.
The meta-analysis included a total of 9 trials incorporat-
ing 1,056 patients. Direct medical costs for prostaglandin
E2 was $1,852.14 and $1,941.51 for misoprostol. Eighty-
five percent of patients receiving misoprostol and 71% of
patients receiving prostaglandin E2 achieved vaginal de-
livery before the use of an alternative method. CON-
CLUSION: Though misoprostol is less expensive per
dose compared to prostaglandin E2, the overall treatment
costs are higher when encompassing costs associated with
adverse effects. Therefore, an incremental cost analysis
demonstrates that if the hospital is willing to pay $638
more per patient, there will be a 1% greater chance of
achieving vaginal delivery.
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THE EFFECT AND ECONOMIC IMPACT OF 
STANDARDIZED ORDERS ON THE PREVENTION 
AND TREATMENT OF PONV IN HOSPITALIZED 
GYNECOLOGICAL SURGERY PATIENTS
Marra C, St. Pierre E, Frighetto L
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OBJECTIVES: The risk of post-operative nausea and
vomiting (PONV) following gynecological surgery re-
mains high despite effective prophylactic medications.
Thus, the objectives of this study were to determine if
standardized orders for the prophylaxis and treatment of
PONV in gynecological surgery patients: 1) reduce
PONV occurrence; 2) reduce total costs; and 3) influence
the choice of medications used for PONV prophylaxis
and treatment. METHODS: A retrospective design was
employed in which a random sample of 200 patients was
selected from each of the two 6 month phases before
(pre) and after (post) the implementation of standardized
orders for PONV prophylaxis and treatment. The pri-
mary outcome was the occurrence of any PONV episode.
Logistic regression was used to adjust for potential con-
founding factors. RESULTS: Characteristics were similar
except for surgical and anesthesia length between phases.
The proportion of patients receiving PONV prophylaxis
increased from 31% (pre) to 47% (post, p  0.002).
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There was a reduction in the risk of a PONV event in the
post phase (OR  0.67, 95% CI 0.67 to 0.97, p  0.04).
The risk of PONV was significantly reduced with the ad-
ministration of prophylactic medications (OR  0.46,
95% CI 0.46 to 0.67). There was a reduction in the mean
number of PONV episodes in the post phase (1.81
events) versus the pre phase (1.47 events, p  0.02). A re-
duction in mean PONV management costs was observed
in the post phase ($8.31, SD 8.50) as compared to the
pre-phase ($10.23, SD 8.25, p  0.02). For mean pro-
phylactic costs, these were significantly higher in the
post-implementation phase when compared to the pre-
implementation phase ($1.64, SD 3.36 vs. $0.91, SD
2.43, p  0.013). Univariate sensitivity analyses revealed
that the economic results were sensitive to several param-
eters. CONCLUSION: The implementation of pre-printed
order forms for PONV prophylaxis and treatment appears
to be an effective and economically attractive strategy.
PWM8
QUALITY OF LIFE IN POST-MENOPAUSAL 
WOMEN IN FIVE EUROPEAN COUNTRIES
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OBJECTIVES: Whilst differences between Caucasian,
African and Asian menopausal women have been well
documented, the aim of this study is to explore the rela-
tionship between menopause, HRT use and aspects of
quality of life (QoL) across five European countries.
METHODS: A large-scale observational study of
women’s health in France, Germany, Italy, Poland, UK
was conducted with 7806 women, aged 45–65, and con-
sulting gynecologists or primary care physicians (n 
530). QoL was assessed with the Women’s Health Ques-
tionnaire (vasomotor, depressed mood and sexual behav-
ior scales). RESULTS: Mean age (range 52.5 to 54.7) and
time since menopause were similar across all countries.
Findings suggested differential use of HRT across Europe
(current or lapsed): high in Germany (68%), low in
France (50%) and Italy (49%) (chi-square  139, P 
0.001). We compared aspects of QoL between users and
non-users (stratified by time since menopause). Within 5
years of menopause HRT users experienced: significantly
fewer vasomotor symptoms than non-HRT users across
all countries (z  15,9 p  0.001); significantly less de-
pression (z  10.5, P  0.001) across all countries ex-
cept the UK, and significantly better sexual functioning in
Italy and Germany (z  7.6, p  0.001). For women
experiencing menopause over 5 years ago, HRT users
had better scores in sexual (z  12.2, P  0.001) and
mood (z  3.0, P  0.002) domains than non-users in
all countries, but no differences were observed for vaso-
motor symptoms. CONCLUSIONS: Within 5 years of
menopause, HRT improves those aspects of menopausal
symptoms which are most important to women at that
time in their lives (vasomotor symptoms, mood) irrespec-
tive of country. After 5 years, across countries, the im-
pact of vasomotor symptoms on women naturally de-
creases and thus HRT users no longer experience a
benefit over non-users. However, the benefits of HRT on
sexual functioning and mood continue. These findings
suggest that pooling European WHQ data may be appro-
priate.
NO SPECIFIC OR MULTIPLE
DISEASES-HEALTH POLICY
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THE ECONOMICS OF PARALLEL TRADE IN 
PHARMACEUTICALS: EXPERIENCES
FROM SWEDEN
Persson UB, Anell A
IHE, The Swedish Institute for Health Economics, Lund, 
Sweden
OBJECTIVES: To analyse the impact of parallel trade of
pharmaceuticals on welfare and innovation in the long
run and to estimate the impact of costs for pharmaceuti-
cals in some therapeutic areas in the short run. METH-
ODS: Identify arguments for and against parallel trade by
use of literature review and by interviewing agens in-
volved in parallel trade of pharmaceuticals. Official data
of prices and sales of pharmaceuticals are used to esti-
mate the impact of parallel trade on the drug bill. RE-
SULTS: In Europe the principle of free trade and the
harmonization of registration requirements for pharma-
ceuticals tend to force price convergence across markets,
i.e. a uniform ‘Euro price’. Parallel trade have reduced
annual costs for pharmaceuticals for treating ulcer re-
lated diseases by about 19 percent and for the treatment
of inhaled steroids of about 8 percent in Sweden. These
cost savings are compared with the excess costs for the
distribution and storage of parallel-imported products.
Comparison shows net cost savings for the ulcer related
diseases and inhaled steroids in the short run. CONCLU-
SIONS: There is a conflict between the principle of free
trade and the principle of intellectual property rights
(e.g., patent, brand-names, etc.). The purpose of intellec-
tual property rights is to provide economic incentives for
the innovative industry to develop new medicines. New
medicines are products with relatively high R&D costs,
difficult to finance without patent protection and price
discrimination.
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ATTITUDE OF PHYSICIANS TOWARD 
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